SABCS 2020 | AMEERA-3: SERD for ER+ HER2- breast cancer
Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an update on the AMEERA-3 (NCT04059484), ongoing Phase II study of SAR439859, an oral selective estrogen receptor degrader (SERD), versus endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with prior exposure to hormonal therapies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
Disclosures
Dr. Tolaney has served in a consulting or advisory role for AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Cyclacel, Sanofi, Celldex, Odonate, Seattle Genetics, Daiichi Sankyo, Silverback Therapeutics, G1 Therapeutics, Abbvie, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Samsung Bioepsis Inc., CytomX, Gilead, Certara, Mersana Therapeutics.
